Industry Roundup: Nicotine Exposure ANPR, Athena Petition Denied
This article was originally published in The Tan Sheet
Executive Summary
Comments sought for nicotine-exposure ANPR; Supreme Court denies Athena petition; Neuragen U.S. market rights; Prestige ‘TMI’ about Monistat; and more news in brief.
You may also be interested in...
Athena Appeal Decision Could Open ‘Floodgate’ For False Claims Litigation
Lower court decisions that Athena Cosmetics’ RevitaLash products is an unapproved drug competing unfairly against Allergan's Latisse drug could have broader implications if the Supreme Court denies the firm's request for review. Already beleaguered by class actions following FDA warnings, firms could face more opportunistic lawsuits if federal courts are left to determine a product's intended use and regulatory status.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.